188 filings
6-K
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
6-K
ARGX
Argen X SE
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
20-F
2023 FY
ARGX
Argen X SE
Annual report (foreign)
21 Mar 24
6:22am
6-K
1saiqfk3u3ck0bsng0eo
21 Mar 24
Current report (foreign)
6:07am
6-K
dszehtpptmyq8yp8kj
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
ycb2nakiicqz18d2ia
29 Feb 24
Current report (foreign)
4:04pm
6-K
qfmjeowdg 3o
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
6-K
5mqj3umsn
18 Jan 24
Current report (foreign)
6:10am
6-K
ii397v8
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
nc7gr9j31
20 Dec 23
Current report (foreign)
6:00am
6-K
zkxzpigymtgcmhuca
28 Nov 23
Current report (foreign)
6:01am
6-K
ib3krlrlr4713d0
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
g6d9e7cib
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
dj1ovxml 4n
31 Oct 23
Current report (foreign)
9:14am
S-8
8684zpnxds36xtm
27 Sep 23
Registration of securities for employees
4:42pm
6-K
7v289wp5e4ky8lvr
21 Sep 23
Current report (foreign)
8:38am
6-K
8av5 lamtqt6l4um
27 Jul 23
Current report (foreign)
6:02am
6-K
emnyjmd0
20 Jul 23
Current report (foreign)
5:44pm